Form 4: Corcept Director Mahoney Exercises Options, Transfers Shares

Corcept Therapeutics Director David L. Mahoney exercised stock options and subsequently transferred shares to a family trust, with some shares withheld for tax obligations.

Summary

• David L. Mahoney, a Director of Corcept Therapeutics Inc. (CORT), exercised 30,000 stock options on March 13, 2026, at an exercise price of $5.86 per share.
• Following the exercise, 5,469 shares were withheld by the company at a price of $32.15 per share to satisfy tax obligations arising from the cashless option exercise.
• The remaining 24,531 shares were transferred without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.
• After these transactions, Mahoney's indirect beneficial ownership includes 1,237,145 shares held by the family trust and 46,147 shares held by The Black Dog Private Foundation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine for an insider exercising options and managing personal holdings, without indicating a strong positive or negative sentiment towards the company's immediate future.

Positives

• The exercise of options indicates the director is realizing value from previously granted equity, which can be seen as a positive for the individual.
• The exercise price of $5.86 is significantly lower than the $32.15 price at which shares were withheld for taxes, indicating a substantial in-the-money value for the options.

Negatives

• The transactions primarily involve the exercise of expiring options and subsequent transfer to a family trust, rather than an open market purchase, which might otherwise signal strong confidence in future stock performance.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as option exercises and transfers to family trusts, are common events in the biotechnology and pharmaceutical sectors, reflecting standard equity compensation practices and personal financial planning for executives and directors. These types of filings generally do not indicate significant shifts in company strategy or market outlook unless they involve large, uncharacteristic open-market sales or purchases.

Related Party Transactions

• Transfer of 24,531 shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.

Stakeholder Impact

• Shareholders: The transactions are routine and do not directly impact the company's operational performance or financial health. They reflect a director's management of personal equity holdings.
• Employees: No direct impact on employees.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of stock options and subsequent transfer of shares to a family trust, along with tax withholding. This type of transaction is common for directors managing their equity compensation and does not provide strong signals for either buying or selling the stock. Therefore, a "hold" recommendation is appropriate as it does not alter the fundamental investment thesis for Corcept Therapeutics.

Keywords

Corcept Therapeutics, CORT, David L. Mahoney, Director, SEC Form 4, beneficial ownership, stock options, option exercise, family trust, insider transaction, equity compensation